51st week of 2009 patent applcation highlights part 35 |
Patent application number | Title | Published |
20090311220 | Bone forming compound composed of a mixture of osteoblast and biomatrix and method for producing the same - A compound for bone forming and a method for producing the same are provided using a mixture of an osteoblast and a bio-matrix. The method comprises: isolating osteoblasts from bone tissue and culturing the isolated osteoblasts to prepare an osteoblast suspension; and mixing the resulting osteoblast suspension with a bio-matrix to prepare an osteoblast therapeutic agent. A bone formation method is provided that results in no clinical graft rejection, and is capable of achieving effective and rapid bone formation via injection of a compound which has been pre-shaped to a certain extent, so as to alleviate problems associated with bone tissue formation in unwanted regions resulting from escape of injected osteoblasts from the targeted site for bone formation and then propagation thereof to other sites via the blood stream, which are caused by injection of an osteoblast suspension. | 2009-12-17 |
20090311221 | BIOMATERIALS FOR REGENERATIVE MEDICINE - It was examined whether a cartilage-like tissue is formed under various reaction conditions using cartilage matrix components: glycosaminoglycan, proteoglycan, and collagen. The present inventors have discovered that proteoglycan bound to glycosaminoglycan through self-organization form an aggregate when the glycosaminoglycan was reacted with proteoglycan under specific concentrations and pH, and that a mesh structure composed of collagen fibers was constructed through self-organization using the aggregates as a skeleton when the aggregates were reacted with collagen molecules. | 2009-12-17 |
20090311222 | TRANSPLANTATION OF NEURAL CELLS - Restoration or increase of inhibitory interneuron function in vivo is achieved by transplantation of MGE cells into the brain. Compositions containing MGE cells are provided as are uses to treat various diseases characterised by abnormal inhibitory interneuron function or in cases where increase inhibition may ameliorate neural circuits that are abnormally activated. | 2009-12-17 |
20090311224 | THERAPEUTIC AGENT COMPRISING LIPOCALIN 2 AGAINST CANCER METASTASIS, AND METHODS OF EARLY DIAGNOSIS AND INHIBITION OF CANCER METASTASIS USING LIPOCALIN 2 - The present invention relates to a pharmaceutical composition for the inhibition of cancer metastasis, more precisely, a novel pharmaceutical composition against cancer metastasis comprising lipocalin 2 protein, a gene encoding the protein, an expression vector containing the gene or cells transfected with the expression vector as an effective ingredient, a method for the inhibition of cancer metastasis using the composition, a diagnostic kit for the prediction of cancer metastasis, a method for the selection of a metastasis risk group using the kit, a novel pharmaceutical composition for the inhibition of cancer growth and a method for the inhibition of cancer growth using the same. The pharmaceutical composition of the present invention specifically inhibits cancer metastasis, so that it can improve the effect of cancer treatment dramatically. And, the diagnostic kit and the method for the selection of a metastasis risk group using the kit enable the selection of a metastasis risk group by measuring the level of lipocalin 2 in tumor tissues or in body fluid. Therefore, the kit and the method can contribute to the effective clinical control of a cancer patient. Further, the composition of the invention can be effectively used for the treatment of liver cancer owing to its liver cancer growth inhibitory effect. | 2009-12-17 |
20090311225 | Compositions of and Methods of Using Stabilized PSMA Dimers - The invention includes cysteine-modified PSMA polypeptides and disulfide-bond-stabilized dimers thereof, compositions and kits containing the cysteine-modified PSMA polypeptides, including dimers thereof, as well as methods of producing and using these compositions. Such methods include methods for eliciting or enhancing an immune response to cells expressing PSMA, methods of producing antibodies to PSMA, including dimeric PSMA, as well as methods of treating cancer, such as prostate cancer. | 2009-12-17 |
20090311226 | COMPOSITION AND METHOD FOR TREATING ESOPHAGEAL DYSPLASIA - Enhancing the immune response to esophageal tumor cells reduces the incidence of esophageal cancer developing, recurring, or metastasizing. Esophageal cancer cells are modified to render them more immunogenic and proliferation compromised. They are used in an antigenic preparation to raise a T cell response in the recipient. | 2009-12-17 |
20090311227 | Composition - The present invention relates to a composition comprising: i) at least one strain of a | 2009-12-17 |
20090311228 | TREATMENT OF INFLAMMATORY BOWEL DISEASE - A method of treating inflammatory bowel disease (IBD) comprises collecting regulatory T cells in an activated or non-activated state from a patient's sentinel lymph nodes draining bowel segments with or without IBD, optionally activating the cells by contacting them with a cytokine and an antigen extract obtained from an inflamed bowel segment, expanding the T cells in vitro, and re-infusing the expanded T cell to the patient. Also disclosed are methods for obtaining sentinel nodes, for expanding T cells, for re-establishing the T | 2009-12-17 |
20090311229 | Isolation and Identification of Cross-Reactive T Cells - Cross-reactive T cells recognizing both MBP | 2009-12-17 |
20090311230 | SYNTHETIC CATALYTIC FREE RADICAL SCAVENGERS USEFUL AS ANTIOXIDANTS FOR PREVENTION AND THERAPY OF DISEASE - The invention provides antioxidant salen-metal complexes, compositions of such antioxidant salen-metal complexes having superoxide activity, catalase activity, and/or peroxidase activity, compositions of salen-metal complexes in a form suitable for pharmaceutical administration to treat or prevent a disease associated with cell or tissue damage produced by free radicals such as superoxide, and cosmetic and free radical quenching formulations of salen metal compounds. | 2009-12-17 |
20090311231 | PRODUCT AND PROCESS FOR LIQUEFACTION OF MUCUS OR SPUTUM - Disclosed are compositions and methods for decreasing the viscosity and/or cohesiveness of and/or increasing the liquefaction of excessively or abnormally viscous or cohesive mucus or sputum. The composition contains a protein or peptide containing a thioredoxin active-site in reduced state and optionally further contains a reducing system. | 2009-12-17 |
20090311232 | Agent for use in the case of fructose intolerance - There is provided in accordance with embodiments of the invention a method of treating or reducing the effects in a subject of a condition selected from fructose intolerance and impaired fructose metabolism, the method comprising administering to a subject in need of such treatment or reduction an efficacious amount of a glucose isomerase, other than in combination with 5-D-fructose dehydrogenase. Other embodiments are also disclosed. | 2009-12-17 |
20090311233 | MATERIALS AND METHODS DIRECTED TO ASPARAGINE SYNTHETASE AND ASPARAGINASE THERAPIES - Materials and Methods for use in treating cell proliferative disorders related to asparagine metabolism are provided. Cell proliferative disorders include such cancers as forms of leukemia, ovarian cancers, melanomas, renal cancers, breast cancers, brain cancers, and other cancers. Methods include the use of RNA interference targeted at asparagine synthetase to enhance the efficacy of L-asparaginase therapies. | 2009-12-17 |
20090311234 | USE OF BETA-LACTAMASE - Class A beta-lactamase may be used for reducing side-effects in the intestine associated with antibiotic therapy with a combination of beta-lactam antibiotic and beta-lactamase inhibitor. | 2009-12-17 |
20090311235 | Use of Polymeric Materials with Other Substances for Improved Performance - Methods of enabling or improving the ability of a hydrogel to swell in the stomach of an animal and/or increasing the amount of time said hydrogel remains swollen in the stomach are described herein. In one embodiment, a polymer is administered in combination with one or more pH modifying agents which raise and maintain the pH of the micro environment of the polymer and/or the stomach in order inducing swelling in the polymer. The polymer can be a homopolymer, a copolymer, or a polymer blend or composite. In one embodiment, the polymer is a superabsorbent polymer (“SAP”). The polymers can also be administered with one or more active agents, such as appetite suppressants. The pH modifying agent and/or the active agent can be administered simultaneously with the polymer in the same dosage form, simultaneously with the polymer in separate dosage forms, or sequentially. The compositions are formulated for oral administration. The formulation can include drugs for delivery to the stomach, such as antibiotics, or the hydrogel can be used as a filler, for example, for obesity control. The formulation an also be used to enhance gastric retention, for example, for controlled drug delivery. Methods of delivering a drug are also described herein, along with medicaments for carrying out the methods of the present invention. | 2009-12-17 |
20090311236 | Therapeutic Peptide Compositions And Methods Of Making And Using Same - Therapeutic compositions include peptide formulations having a mixture of serum, albumin, casein, peptone, pacreatin, and sodium hydroxide. The peptide compositions do not include nucleic acid or any derivatives thereof. The peptide compositions have beneficial therapeutic properties to boost human immune system and to treat various ailments including malaria, allergy and inflammation. The peptide compositions, one having a molecular weight greater than 10 kDa and having amino acid residues in a range of 27 and 315, and the other having a molecular weight equal to or less than 10 kDa and amino acid residues in a range of 27 and 54, their structures and therapeutic properties are discussed. | 2009-12-17 |
20090311237 | Combination therapy using a soluble hyaluronidase and a bisphosphonate - Provided are combinations, compositions and kits containing a bisphosphonate composition and a soluble hyaluronidase composition formulated for subcutaneous administration. Such products can be used in methods of treating bisphosphonate-treatable diseases or conditions. Also provided are methods for subcutaneous administration of a bisphosphonate compound whereby the dosing regimen is substantially the same as for intravenous administration of the same dosage for treatment of the same bisphosphonate-treatable disease or condition. | 2009-12-17 |
20090311238 | TOPICAL COMPOSITION AND TREATMENT METHOD FOR CARTILAGE DAMAGE - A method of treating cartilage damage by topically administering an effective amount of a pharmaceutical composition comprising (a) a substance P inhibitor and (b)a proteolytic enzyme with an suitable pharmaceutical carrier. The pharmaceutical composition is capable of promoting cartilage regeneration in animal and human subjects. | 2009-12-17 |
20090311239 | RECOMBINANT OR TRANSGENIC FACTOR VII COMPOSITION, EACH FACTOR VII MOLECULE HAVING TWO N-GLYCOSYLATION SITES WITH DEFINED GLYCAN UNITS - The invention is related to a composition of recombinant or transgenic Factor VII, each molecule of Factor VII of the composition exhibiting two N-glycosylation sites, wherein, among all the molecules of FVII of the composition, the rate of Galα1,3Gal glycan moieties is comprised between 0 and 4%. The invention is also related to a process for preparing such a composition of FVII | 2009-12-17 |
20090311240 | VEGF165 Delivered by Fibrin Sealant to Reduce Tissue Necrosis - The present application demonstrates the clinical potential of fibrin sealants to locally deliver growth factors to ischemic tissue. More particularly, it demonstrates that hydrogels such as Fibrin Sealants can be used to deliver VEGF | 2009-12-17 |
20090311241 | Human antibodies that bind human IL-12 and methods for producing - Human antibodies, preferably recombinant human antibodies, that specifically bind to human interleukin-12 (hIL-12) are disclosed. Preferred antibodies have high affinity for hIL-12 and neutralize hIL-12 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hIL-12 and for inhibiting hIL-12 activity, e.g., in a human subject suffering from a disorder in which hIL-12 activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention. | 2009-12-17 |
20090311242 | Diagnostics and therapeutics for diseases associated with 5-hydroxytryptamine 2a receptor (5ht2a) - The invention provides a human 5HT2a which is associated with the cardiovascular diseases, respiratory diseases, dermatological diseases, gastroenterological diseases, cancer, inflammation, metabolic diseases, hematological diseases, muscle skeleton diseases, neurological diseases, urological diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular diseases, respiratory diseases, dermatological diseases, gastroenterological diseases, cancer, inflammation, metabolic diseases, hematological diseases, muscle skeleton diseases, neurological diseases, urological diseases. The invention also features compounds which bind to and/or activate or inhibit the activity of 5HT2a as well as pharmaceutical compositions comprising such compounds. | 2009-12-17 |
20090311243 | Methods for Identifying FZD8 Modulators and the Use of such Modulators for Treating Osteoarthritis - Methods and kits for identifying agents that modulate the function of the Methods and kits for identifying agents that modulate the function of the receptor Fzd8 are provided. Accordingly, the present invention makes available methods for identifying agents useful as modulators of Wnt-Fzd8 signalling. Therapeutic uses of the identified agents for treating osteoarthitis are also provided. | 2009-12-17 |
20090311244 | Screening Method - This invention relates to a novel screening method that identifies simple molecular markers that are predictive of whether a particular disease condition is responsive to a specific treatment. Also, a method of diagnosing the susceptibility of an individual suffering from a disease to treatment with an HDAC inhibitor is provided. Also provided is a method of treating a proliferative disease or a condition which involves a change in cell differentiation or growth rate in a patient. | 2009-12-17 |
20090311245 | METALLOPROTEINASE 9 BINDING PROTEINS - Proteins that bind to matrix metalloproteinase 9 and methods of using such proteins are described. | 2009-12-17 |
20090311246 | Method of Enhancing Remyelination in Demyelinating Diseases of the Central Nervous System - The present invention provides methods for enhancing remyelination or decreasing or inhibiting demyelination in central nervous system (CNS) of a mammalian subject by administering to the subject an effective amount of a Semliki Forest Virus (SFV) epitope E2 137-151 peptide together with a pharmaceutically acceptable carrier, or an antibody to E2 137-151 peptide (“E2 137-151 antibody”). The present invention also provides a method for treating a CNS disease, particularly, multiple sclerosis (MS), in a mammalian subject by administering to the subject a therapeutically effective amount of an E2 137-151 peptide together with a pharmaceutically acceptable carrier, or an anti E2 137-151 antibody. A polyclonal and a monoclonal E2 137-151 antibody are also provided by the present invention. | 2009-12-17 |
20090311247 | MOLECULES AND CHIMERIC MOLECULES THEREOF - The present invention relates generally to the fields of proteins, diagnostics, therapeutics and nutrition. More particularly, the present invention provides an isolated protein molecule such as EPO, Flt3-Ligand, Flt3, PDGF-B or VEGF-165 or chimeric molecules thereof comprising at least a portion of the protein molecule, wherein the protein or chimeric molecule has a profile of measurable physiochemical parameters which is indicative of, associated with or forms the basis of, one or more pharmacological traits. The present invention further contemplates the use of the isolated protein or chimeric molecule thereof in a range of diagnostic, prophylactic, therapeutic, nutritional and/or research applications. | 2009-12-17 |
20090311248 | Hepatitis C Virus Neutralizing Antibodies - The invention relates to anti-HCV antibodies and more specifically to neutralizing anti-HCV antibodies and their variable and complementarity determining regions (CDR). In particular, the neutralizing anti-HCV antibodies are neutralizing anti-HCV envelope protein 1 (HCV E1) antibodies. Also subject of the invention are compositions comprising these antibodies, CDRs or variable regions, and compounds comprising at least one of the CDRs or variable regions of said antibodies. Further subject of the invention are the application of any of said antibodies, CDRs, variable regions or compounds in HCV prophylaxis, therapy, and diagnosis, as well as methods for producing the antibodies. | 2009-12-17 |
20090311249 | Capecitabine Combination Therapy - The invention provides the use of a combination of an mTOR inhibitor and capecitabine in the treatment of cancer. | 2009-12-17 |
20090311250 | METHODS AND COMPOSITIONS FOR THE DIAGNOSIS AND TREATMENT OF CANCER - Methods and compositions are provided for the diagnosis and treatment of colorectal cancers associated with amplification or overexpression of the FGFR2 gene. | 2009-12-17 |
20090311251 | SCFV ANTIBODIES WHICH PASS EPITHELIAL AND/OR ENDOTHELIAL LAYERS - scFv antibodies which specifically bind selected antigens and are obtainable by a method comprising (i) selecting from a pool of soluble and stable antibody frameworks a soluble and stable framework matching best the framework of a non-human antibody against the antigen with a certain binding specificity, (ii) either providing said soluble and stable framework with CDRs that bind specifically to said antigen, or mutating the framework of said non-human antibody towards the sequence of said soluble and stable framework, to generate scFv antibodies, (iii) testing the generated antibody for solubility and stability, and testing the generated antibody for antigen binding, and (iv) selecting an scFV that is soluble, stable and binds to the antigen specifically. Also provided are pharmaceutical compositions comprising said scFv antibody, methods of treatment and diagnosis for diseases related to over expression of antigens that are specifically bound by said antibody. | 2009-12-17 |
20090311252 | Anti-activin antibodies and uses for promoting bone growth - In certain aspects, the present invention provides compositions and methods for promoting bone growth and increasing bone density. | 2009-12-17 |
20090311253 | Dual Variable Domain Immunoglobulins and Uses Thereof - The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease. | 2009-12-17 |
20090311254 | CD40 ANTIBODY FORMULATION AND METHODS - The present invention provides a method of treating tumor in a patient comprising administering to said patient a CD40 agonist antibody according to an intermittent dosing schedule. The present invention also provides a method of treating tumor in a patient comprising administering a combination of a CD40 agonist antibody and a DNA replication inhibitor. Also provided is a formulation for use in the treatment. | 2009-12-17 |
20090311255 | PREVENTING AUTOIMMUNE DISEASE - The present application describes a method of preventing an autoimmune disease in an asymptomatic human subject at risk for experiencing one or more symptoms of the autoimmune disease, by administering a CD20 antibody to the subject in an amount to prevent the subject from experiencing one or more symptoms of the autoimmune disease. | 2009-12-17 |
20090311256 | 12 Human Secreted Proteins - The present invention relates to 12 novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human secreted proteins. | 2009-12-17 |
20090311257 | HUMAN ANTIBODIES SPECIFIC FOR GASTRIN MATERIALS AND METHODS - The present invention relates to materials and methods for human antibodies specific for the peptide hormone gastrin and uses of these antibodies in the treatment of subjects having cancer and other conditions or disorders related to gastrin expression. | 2009-12-17 |
20090311258 | MEDICAMENT FOR LCT POISONING - The medicament for the prevention or the relief of poisoning by large clostridial cytotoxins (LCTs), in particular | 2009-12-17 |
20090311259 | Compositions and Methods for Treatment of Tumor of Hematopoietic Origin - The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same. | 2009-12-17 |
20090311260 | Compositions and methods for the diagnosis and treatment of inflammatory bowel disorders - The present invention is directed to compositions of matter useful for the diagnosis and treatment of inflammatory bowel diseases in mammals and to methods of using those compositions of matter for the same. | 2009-12-17 |
20090311261 | Compositions and methods for the diagnosis and treatment of inflammatory bowel disorders - The present invention is directed to compositions of matter useful for the diagnosis and treatment of inflammatory bowel diseases in mammals and to methods of using those compositions of matter for the same. | 2009-12-17 |
20090311262 | Method for Diagnosing Cancers Expressing the HER2 Receptor or its Truncated Variants - The present invention relates to a method of diagnosis and therapy of cancers expressing the HER2 receptor. | 2009-12-17 |
20090311263 | HUMAN VASCULAR IBP-LIKE GROWTH FACTOR - A human Vascular IBP-Like Growth Factor polypeptide (VIGF) and DNA (RNA) encoding such polypeptide and a procedure for producing such polypeptide by recombinant techniques is disclosed. Also disclosed are methods for utilizing such polypeptide for wound healing or tissue regeneration, stimulating implant fixation and angiogenesis. Antagonist against such polypeptides and their use as a therapeutic to treat atherosclerosis, tumors and scarring are also disclosed. Diagnostic assays for identifying mutations in VIGF nucleic acid sequences and altered levels of the VIGF polypeptide are also disclosed. | 2009-12-17 |
20090311264 | Use of Disorazoles and Their Derivatives for the Treatment of Benign and Malignant Oncoses - The invention relates to disorazoles of the general formula I, which are employed as medicaments, preferably for the treatment of oncoses, in particular in the case of pharmaceutical resistance to other active compounds and in the case of metastasizing carcinoma. The possible uses are not restricted to oncoses. | 2009-12-17 |
20090311265 | Human binding molecules capable or neutralizing influenze virus h5n1 and uses thereof - The present invention relates to binding molecules such as human monoclonal antibodies that bind to influenza virus H5N1 and have neutralizing activity against influenza virus H5N1. The disclosure provides nucleic acid molecules encoding the antibodies, their sequences and compositions comprising the antibodies and methods of identifying or producing the antibodies. The antibodies can be used in the diagnosis, prophylaxis and/or treatment of an influenza virus H5N1 infection. In a preferred embodiment, the antibodies provide cross-subtype protection in vivo, such that infections with H5, H2, H6, H9 and H1-based influenza subtypes can be prevented and/or treated. | 2009-12-17 |
20090311266 | Inhibitors of the endothelin signalling pathway and alphavbeta3 integrin receptor antagonists for combination therapy - The invention relates to the use of an endothelin blocker in combination with an α | 2009-12-17 |
20090311267 | Inhibition of VWF - GPIb/V/IX interaction and platelet-collagen interaction for prevention and treatment of cerebral attacks - The invention relates generally to an anti-thrombotic treatment of occlusive syndromes in the cerebral vascular system causing cerebral infarct due to stroke or ischemic stroke, which is a major cause of death and permanent disability in industrialized countries. More particularly, the invention relates to a system and method of preventing and treating such occlusive syndromes in the cerebral vascular by inhibiting initial adhesion/attachment of platelets to the endothelium by preventing or inhibiting binding of von Willebrand factor to platelet glycoprotein Ib by administration of a subject in such need anti-glycoprotein Ib monovalent antibodies and/or anti-vWF monovalent antibodies, rather than by blocking the common pathway of platelet aggregation by blockade of platelet aggregation with anti-glycoprotein IIb/IIIa. | 2009-12-17 |
20090311268 | CD40-BINDING ACTIVATING ANTIBODIES - Disclosed are agonist anti-CD40 molecules, including monoclonal antibodies, which can bind to and stimulate professional and non-professional human antigen-presenting cells (“APCs”), enhance the stimulatory effect of CD40L on CD40 positive cells and/or induce phenotypical maturation of monocyte derived dendritic cells. Several such monoclonal antibodies are provided, and cell lines producing them have been deposited at the American Type Culture Collection. | 2009-12-17 |
20090311269 | Methods for collecting and detecting oligonucleotides - Methods, pharmaceutical compositions, and kits are provided which includes accurately sampling a RNA from a tissue of an animal and analyzing RNA in the tissue of the animal as an indicator of physiological state, infectious disease, neoplastic disease, autoimmune disease, inflammatory disease, cardiovascular disease, atherosclerotic disease, or neurological disease in the animal. A method is provided which includes administering at least one compound to an animal wherein the at least one compound is configured to prevent the cleavage of at least one tissue RNA by a ribonuclease. The method further includes collecting a sample of at least a portion of tissue from the animal. | 2009-12-17 |
20090311270 | Methods, compositions, and kits for collecting and detecting oligonucleotides - Methods, pharmaceutical compositions, and kits are provided which includes accurately sampling a RNA from a tissue of an animal and analyzing RNA in the tissue of the animal as an indicator of physiological state, infectious disease, neoplastic disease, autoimmune disease, inflammatory disease, cardiovascular disease, atherosclerotic disease, or neurological disease in the animal. A method is provided which includes administering at least one compound to an animal wherein the at least one compound is configured to prevent the cleavage of at least one tissue RNA by a ribonuclease. The method further includes collecting a sample of at least a portion of tissue from the animal. | 2009-12-17 |
20090311271 | Methods and Compositions for Selective Inhibition of Ligand Binding to the Lectin-Like Receptor for Oxidized Low Density Lipoprotein (LOX-1) - The present invention provides methods of selectively inhibiting the binding of one ligand for LOX-1, but not one other ligand for LOX-1. Moreover, the invention relates to the identification of binding partners that act in a selective manner to inhibit the binding of one ligand to LOX-1, but not one other ligand for LOX-1, and methods of identifying such binding partners. Pharmaceutical compositions comprising the binding partners for LOX-1, in particular, anti-LOX-1 antibodies or fragments thereof, are also provided in the present invention. | 2009-12-17 |
20090311272 | METHODS AND COMPOSITIONS FOR MODULATING ANGIOGENESIS AND PERICYTE COMPOSITION - In certain aspects, the present disclosure relates to the insight that a polypeptide comprising a ligand-binding portion of the extracellular domain of activin-like kinase I (ALK1) polypeptide may be used to inhibit angiogenesis in vivo, particularly in mammals suffering angiogenesis-related disorders. Additionally, the disclosure demonstrates that inhibitors of ALK1 may be used to increase pericyte coverage in vascularized tissues, including tumors and the retina. The disclosure also identifies ligands for ALK1 and demonstrates that such ligands have pro-angiogenic activity, and describes antibodies that inhibit receptor-ligand interaction. | 2009-12-17 |
20090311273 | TREATMENT OF MULTIPLE SCLEROSIS AND/OR RHEUMATOID ARTHRITIS - The invention relates to the use of an antibody which can specifically bind to chemokine receptor CCR2 for producing a medicament utilized for the treatment of multiple sclerosis and/or rheumatoid arthritis in a subject that is preferably a primate or a human. In another embodiment, the invention relates to the use of an antibody which can specifically bind to chemokine receptor CCR2 for producing a medicament that is utilized for depleting monocytes in subjects suffering from multiple sclerosis and/or rheumatoid arthritis. The invention further relates to corresponding in vitro methods and therapeutic methods. And antibody which binds to CD 14, for example, can be used in addition to the antibody that can bind to CCR2. | 2009-12-17 |
20090311274 | NUCLEIC ACID AND CORRESPONDING PROTEIN ENTITLED 238P1B2 USEFUL IN TREATMENT AND DETECTION OF CANCER - A novel gene (designated 238P1B2) and its encoded protein, and variants thereof, are described wherein 238P1B2 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 238P1B2 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 238P1B2 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 238P1B2 can be used in active or passive immunization. | 2009-12-17 |
20090311275 | Carrier for targeting nerve cells - The present invention relates to a transport protein which can be obtained by modifying the heavy chain of the neurotoxin formed by | 2009-12-17 |
20090311276 | NANOLIPOPROTEIN PARTICLES AND RELATED COMPOSITIONS, METHODS AND SYSTEMS - Functionalized nanolipoprotein particle presenting an anchor substrate compound for binding with a corresponding anchor compound presented on a target molecule, and related compositions methods and systems. | 2009-12-17 |
20090311277 | NUCLEIC ACID COMPOSITIONS FOR STIMULATING IMMUNE RESPONSES - The invention provides an immunostimulatory nucleic acid comprising CpG motifs, and methods of use thereof in stimulating immunity. | 2009-12-17 |
20090311278 | Novel teleost derived antimicrobial polypeptides - The invention is directed to an isolated polypeptide which (a) is obtainable from a teleost; (b) has antimicrobial activity; (c) binds to oligoguanosine and/or CpG (SEQ ID NO:7); (d) comprises 58 strongly basic amino acids selected from the group consisting of K and R; (e) comprises 50 hydrophobic amino acids selected from the group consisting of A, I, L, F, W and V; (f) comprises 50 polar amino acids selected from the group consisting of N, C, Q, S, T and Y and (g) contains 11 lysine-rich motifs and antimicrobial fragments thereof as well as methods for preparing said polypeptides, compositions and libraries comprising said polypeptide(s) and uses of said polypeptide(s), particularly in treating microbial infections. The invention is further directed to a nucleic acid(s) encoding said polypeptide, microarrays comprising said nucleic acid(s) and uses for said nucleic acid(s). Furthermore, the invention is directed to an antibody which birds to the polypeptide of the present invention and uses for said antibodies. | 2009-12-17 |
20090311279 | Colorectal Cancer Antigen - A point mutation at position 399 in a commonly expressed gene, designated as COA-1 herein, is diagnostic of colorectal cancer and is capable of eliciting at all mediated immune response. | 2009-12-17 |
20090311280 | NOVEL TNF RECEPTOR REGULATORY DOMAIN - Herpesvirus entry mediator (HVEM) is a member of the tumor necrosis factor receptor superfamily (TNFRSF) and acts as a molecular switch that modulates T cell activation by propagating positive signals from the TNF related ligand, LIGHT (p30, TNFSF14), or inhibitory signals through the immunoglobulin superfamily member, B and T lymphocyte attenuator (BTLA). A novel binding site for BTLA is disclosed, located in cysteine-rich domain-1 of HVEM. BTLA binding site on HVEM overlaps with the binding site for the Herpes Simplex virus-1 envelope glycoprotein D (gD), but is distinct from where LIGHT binds, yet gD inhibits the binding of both ligands. A BTLA activating protein present in human cytomegalovirus is identified as UL144. UL144 binds BTLA, but not LIGHT, and inhibits T cell proliferation. | 2009-12-17 |
20090311281 | NOVEL METHOD FOR DOWN-REGULATION OF AMYLOID - Disclosed are novel methods for combating diseases characterized by deposition of amyloid. The methods generally rely on immunization against amyloidogenic proteins (proteins contributing to formation of amyloid) such as beta amyloid (Aβ). Immunization is preferably effected by administration of analogues of autologous amyloidogenic polypeptides, said analogues being capable of inducing antibody production against the autologous amyloidogenic polypeptides. Especially preferred as an immunogen is autologous Aβ which has been modified by introduction of one single or a few foreign, immunodominant and promiscuous T-cell epitopes while substantially preserving the majority of Aβ's B-cell epitopes. Also disclosed are nucleic acid vaccination against amyloidogenic polypeptides and vaccination using live vaccines as well as methods and means useful for the vaccination. Such methods and means include methods for identification of useful immunogenic analogues of the amyloidogenic proteins, methods for the preparation of analogues and pharmaceutical formulations, as well as nucleic acid fragments, vectors, transformed cells, polypeptides and pharmaceutical formulations. | 2009-12-17 |
20090311282 | NEUTRALIZING GDF8 EPITOPE-BASED GROWTH ENHANCING VACCINE - The invention provides new, specific antigenic peptides from the protein GDF8. The invention also provides fusion proteins comprising the new peptides, immunogens and vaccines based on the new peptides and/or fusion proteins, antibodies that specifically bind to the new peptides of GDF8, and methods of treating animals in order to modulate the activity of GDF8, employing vaccines or antibodies according to the invention. | 2009-12-17 |
20090311283 | Inducing cellular immune responses to hepatitis B virus using peptide and nucleic acid compositions - This invention uses our knowledge of the mechanisms by which antigen is recognized by T cells to develop epitope-based vaccines directed towards HBV. More specifically, this application communicates our discovery of pharmaceutical compositions and methods of use in the prevention and treatment of HBV infection. | 2009-12-17 |
20090311284 | Recombinant Viral Proteins And Particles - Disclosed are nucleic acids encoding fusion polypeptides containing the sequence of a Bamboo mosaic virus coat protein or a segment thereof; and an immunogenic heterologous fragment that is fused to the carrier fragment. Also disclosed are related chimeric bamboo mosaic virus particle, related expression vectors, related host cells, and related compositions. Methods of producing and using the fusion polypeptide or chimeric Bamboo mosaic virus particle are also disclosed. | 2009-12-17 |
20090311285 | VACCINE - The present invention relates to immunogenic compositions or vaccines comprising a Vi capsular saccharide-protein carrier conjugate, methods of making the immunogenic compositions or vaccines and uses thereof. | 2009-12-17 |
20090311286 | Alphanizomenon Flos Aquae Preparation, Extracts and Purified Components Thereof for the Treatment of Neurological, Neurodegenerative and Mood Disorders - The invention provides extracts of the microalga | 2009-12-17 |
20090311287 | Novel flavivirus antigens - The invention provides polynucleotides and polypeptides encoded therefrom having advantageous properties, including an ability to induce an immune response to flaviviruses. The polypeptides and polynucleotides of the invention are useful in methods of inducing immune response against flaviviruses, including dengue viruses. Compositions and methods for utilizing polynucleotides and polypeptides of the invention are also provided. | 2009-12-17 |
20090311288 | IMIDAZOQUINOXALINE COMPOUNDS AS IMMUNOMODULATORS - The invention proyides novel compositions comprising imidazoquinoxaline compounds of formula (I) and analogs thereof. Also provided are methods of administering the compositions in an effective amount to enhance the immune response of a subject. Further provided are novel compositions and methods of administering the compositions in combination with (an) other agent (s). | 2009-12-17 |
20090311289 | VACCINE - The present invention relates, in-general, to Human immunodeficiency virus (HIV), and in particular to a carbohydrate-based vaccine for HIV and to methods of making and using same. | 2009-12-17 |
20090311290 | Urogenital or anorectal transmucosal vaccine delivery system - The invention is directed to a suppository based vaccine delivery system for immunizing against urogenital and anorectally transmitted infectious disease in humans and animals and a method for treating the same. More particularly, this invention is directed to a suppository based vaccine delivery system for the prophylaxis against or treatment of urogenital or anorectal transmitted infectious diseases, such as from viral or microbial pathogens. The suppository based delivery system comprises vaccine and/or vaccine adjuvant(s) comprised of whole or fractionated viral or other microbial pathogens, or their purified cellular constituents, whether native, mutated, synthetic, cloned or recombinantly expressed, that consists of nucleic acids, proteins, lipids or other antigenic determinants capable of producing humoral or cellular-mediated immunity in humans or animals; and a polyethylene glycol base; wherein the suppository is adapted to be inserted into a bodily orifice of a human or animal so as to allow the suppository to be in contact with tissue of the bodily orifice to facilitate transfer of vaccine or vaccine adjuvant(s) material therethrough. | 2009-12-17 |
20090311292 | PROCESS FOR SYNTHESIS AND INCORPORATION OF NITRIC OXIDE DONORS IN MACROMOLECULAR COMPOSITIONS - The present invention describes a process for the synthesis of S-nitrosothiols and the subsequent incorporation of these compounds in hydrophilic macromolecular compositions. By the process described herein, the S-nitrosothiols are synthesized in a device (FIG. | 2009-12-17 |
20090311293 | Method and composition for obtaining odor-suppressing textile products and textile products, namely garments, thus obtained - A method of obtaining a textile product having odor-suppressing properties. The product is treated with a composition which comprises, a polymeric binder, in addition to an active ingredient of aluminum chloride, for stably fixing the active ingredient to the product and releasing it gradually over the course of time. The polymeric binder preferably comprises at least one resin selected from a group including: acrylic-based resin, silicone-based resin, butadiene-based resin, polyurethane-based resin, polyamide-based resin and acrylonitrile-based resin. | 2009-12-17 |
20090311294 | ACTIVE DELIVERY ORAL CARE IMPLEMENT - An oral care implement includes a head ( | 2009-12-17 |
20090311295 | PARTICLES WITH HIGH UNIFORM LOADING OF NANOPARTICLES AND METHODS OF PREPARATION THEREOF - Methods to produce polymeric microparticles containing nanoparticles such, as pigments, dyes and other chromophores for cosmetic use, plastic surgery therapeutic use, and tattoos have been developed. The microparticles contain within the polymer a very uniform dispersion of dye particles. The methods by which the particles are made ensure a homogeneous mixture and high loading. The microparticles are made using air, one of a number of known methods such as phase inversion, solvent evaporation, and melt processing. The improvement is in the use of a method that makes, a stable dispersion of the nanoparticles in the liquid polymer before formation of the microparticles. This is achieved through selection of appropriate solvent, optionally including surfactant, and then subjecting the dispersion to mechanical processing that stabilizes the dispersion within the polymer solvent, so that the nanoparticles remain suspended for at least thirty minutes, in some cases two hours to 48 hours, sometimes up to three months. The mechanical processing can be sonication and/or production of shear forces, for examples, resulting from use of an open blade or rotor stator mixer or milling with a concentric shaft, at a speed such as between 5000 and 25,000 RPM. | 2009-12-17 |
20090311296 | Active Agent Delivery and/or Odor Retentive Composition and Methods of Use Thereof - An active agent delivery and/or odor retentive composition including a surfactant and wax spheres formed from at least one of beeswax and soy wax and methods of use thereof. The composition is particularly useful in the cosmetics and medical industry for delivering/carrying a particular ingredient to one's skin, scalp or hair; for absorbing odor causing materials, such as fuel byproducts from a skin surface; and/or for providing exfoliating properties to the skin. The delivery system/carrying system is also useful in binding to certain nutritional materials, such as vitamins, minerals, antioxidants, and the like for ingestion and release into the body. | 2009-12-17 |
20090311297 | Biocompatible Transparent Sheet, Method for Producing the Same, and Cultured Cell Sheet Used the Same Sheet - The present invention provides a flexible, biocompatible transparent sheet ( | 2009-12-17 |
20090311298 | Antimicrobial Collagenous Constructs - Bioengineered collagen constructs with antimicrobial properties are provided. The bioengineered collagen constructs comprise a sheet-like layer of purified collagenous tissue matrix derived from a tissue source, such as the tunica submucosa of small intestine or a processed intestinal collagen layer derived from the tunica submucosa of small intestine, treated with an antimicrobial agent. The constructs are biocompatible. The present invention has a variety of applications, including wound dressing and surgical repair devices. Methods for treating a damaged or diseased soft tissue are provided. Methods for treating a wound in need of care and treatment are also disclosed. | 2009-12-17 |
20090311299 | ANTITHROMBOTIC COATING FOR DRUG ELUTING MEDICAL DEVICES - Medical devices, and in particular implantable medical devices, may be coated to minimize or substantially eliminate a biological organism's reaction to the introduction of the medical device to the organism. The medical devices may be coated with any number of biocompatible materials. Therapeutic drugs, agents or compounds may be mixed with the biocompatible materials and affixed to at least a portion of the medical device. These therapeutic drugs, agents or compounds may also further reduce a biological organism's reaction to the introduction of the medical device to the organism. In addition, these therapeutic drugs, agents and/or compounds may be utilized to promote healing, including the formation of blood clots. Various materials and coating methodologies may be utilized to maintain the drugs, agents or compounds on the medical device until delivered and positioned. | 2009-12-17 |
20090311300 | Stent With a Coating or a Basic Body Containing a Lithium Salt and Use of Lithium Salts for Prevention of Restenosis - The invention relates to a stent with in particular a coated basic body made of an implant material the use of lithium salts as a coating material or a component of an implant material for stents and the use of lithium salts in a method for restenosis prevention. The inventive stent having a basic body made of an implant material is characterized in that (i) the basic body has a coating which comprises or consists of a lithium salt, and/or (ii) the implant material is biocorrodible and the basic body contains a lithium salt. | 2009-12-17 |
20090311301 | COATING CONSTRUCT CONTAINING POLY(VINYL ALCOHOL) - A method of forming a surface layer that includes a hydroxyl polymer on a substrate coating on a medical device is provided. | 2009-12-17 |
20090311302 | HYDROPHILIZED ANTIMICROBIAL POLYMERS - A bactericidal or antimicrobial polymeric composition includes a hydrophilic first comonomer copolymerized to a second comonomer to produce a polymeric composition that is more hydrophilic or more bactericidal or antimicrobial in an aqueous solution than either of the comonomers alone. Methods for identifying bactericidal or antimicrobial polymers, methods for rendering materials bactericidal or antimicrobial, and methods for using bactericidal or antimicrobial compositions to kill or reduce bacterial or microbial growth are also described. Applications for the inventive compositions include their use in catheters, stents, medical devices, contact lenses; root canal fillers; fibers; paper; and/or wound dressing. | 2009-12-17 |
20090311303 | BIODEGRADABLE IMPLANTS FOR BONE FUSION AND COMPOSITIONS THEREFOR - A biodegradable copolymer network, which is particularly suited for use in applications such as interbody implants for bone fusion, is provided. The biodegradable copolymer network of the present invention is biodegradable yet provides sufficient mechanical strength for use in procedures such as spinal fusion. Also provided are methods of producing said biodegradable copolymer network, methods of delivery of biologically active substances, implants comprising said biodegradable copolymer network and methods of administering bioactive and in particular, osteoinductive, substances. | 2009-12-17 |
20090311304 | DRUG-LOADED IMPLANT - The invention relates to a drug-loaded implant having a carrier body ( | 2009-12-17 |
20090311305 | Vaginal therapeutic device including copper metal and method of treating the vaginal using the vaginal therapeutic device - A vaginal therapeutic device made of copper metal has a shape to fit in the vagina and utilizes the copper metal as an antimicrobial agent to therapeutically treat abnormal biological conditions in the vagina. | 2009-12-17 |
20090311306 | Intrauterine contraceptive device - An intrauterine contraceptive device comprising a carrier body ( | 2009-12-17 |
20090311307 | Hydractive Recipe - The invention relates to a method for assembling an adhesive device comprising a first matrix-forming material with holes and a second material, the method comprising:
| 2009-12-17 |
20090311308 | SKINCARE COMPOSITIONS COMPRISING SALICYCLIC ACID - There is disclosed a skincare composition suitable for topical application to the skin. The composition comprises salicylic acid or a salt thereof and hydrolysed milk protein. The composition is useful in the treatment of acne. | 2009-12-17 |
20090311309 | Novel Tissue Support - The present disclosure provides tissue supports which may be utilized by themselves or in combination with other tissue closure means to enhance wound closure and healing. The tissue supports are made of a material which shrinks upon application of heat or light to further support the tissue and/or wound to which it is applied. | 2009-12-17 |
20090311310 | Patch and patch preparation - The present invention provides a patch capable of suppressing adhesive residue on the skin surface upon peeling off from the skin in the presence of water due to perspiration and the like, as well as easy detachment from the skin in the presence of water due to perspiration and the like. The present invention provides a patch comprising a support and an adhesive layer provided on at least one surface of the support, wherein the adhesive layer is formed by crosslinking a blend of the following component (A) to component (D): (A) a copolymer obtained by copolymerization of a monomer containing a carboxyl group, (meth)acrylate and vinylpyrrolidone as essential components; (B) a copolymer obtained by copolymerization of a monomer having a basic group as an essential component; (C) a liquid component, and (D) an acidic compound. | 2009-12-17 |
20090311311 | TRANSDERMAL LOCAL ANESTHETIC PATCH WITH INJECTION PORT - Described herein are transdermal delivery devices composed of at least one re-sealable injection port and at least one local anesthetic reservoir. The device effectively delivers anesthetic to the skin of the subject prior to puncturing the skin by syringes, needle sticks, or other instruments intended to be inserted into the skin. In addition, this device can be used to deliver various therapeutic agents for either locally or systemically. | 2009-12-17 |
20090311312 | Transdermal Hormone Delivery System: Compositions And Methods - A transdermal hormone delivery system (THDS) is disclosed. The THDS is useful for control of fertility and as therapy for a variety of diseases and conditions treatable by robust delivery of progestin and estrogen hormones, particularly the progestin, levonorgestrel. The THDS comprises a backing layer, an adjoining adhesive polymer matrix comprising an effective amount of at least a progestin hormone, delivery of which is enhanced by one or more skin permeation enhancing agents present in pre-determined amounts. The THDS is capable of providing effective daily doses of progestin and estrogen hormones from a small surface area in contact with the skin, e.g., less than 20 square centimeters. Methods of fertility control and various types of hormone replacement therapy utilizing the THDS are also disclosed. | 2009-12-17 |
20090311313 | METHODS FOR TREATING TWEAK-RELATED CONDITIONS - The present invention provides methods and agents for the treatment of TWEAK-related conditions, including cardiac, liver, kidney, lung, adipose, skeletal, muscle, neuronal, bone and cartilage conditions. The invention also provides methods for identifying TWEAK agonists or antagonists for the treatment of TWEAK-related conditions. Additionally, the invention provides transgenic animals that express an exogenous DNA encoding a TWEAK polypeptide, or fragments, analogs, or muteins thereof, and methods for using such animals to identify TWEAK agonists or antagonists. The invention further provides methods for diagnosing a disease based on TWEAK expression. The invention also provides methods for affecting cellular differentiation of progenitor cells using TWEAK polypeptides, agonists, or antagonists. | 2009-12-17 |
20090311315 | Multimicroparticulate Oral Pharmaceutical Form with Modified Release of Angiotensin II Receptor Antagonists - The invention relates to oral pharmaceutical forms with modified release of ARB, and to related treatments and delivery methods. | 2009-12-17 |
20090311316 | TREATING VITAMIN D INSUFFICIENCY AND DEFICIENCY WITH 25-HYDROXYVITAMIN D2 AND 25-HYDROXYVITAMIN D3 - Methods and compositions for treating 25-hydroxyvitamin D insufficiency and deficiency in a patient are described herein. The method includes orally administering to the patient a delayed, sustained release formulation including a first ingredient selected from the group consisting of 25-hydroxyvitamin D | 2009-12-17 |
20090311317 | MODIFIED RELEASE TOLTERODINE FORMULATIONS - Modified or extended release formulations containing tolterodine and associated methods are disclosed and described. Methods for making and administering said modified release formulations are also disclosed. | 2009-12-17 |
20090311318 | SUBSTITUTED (S)-BENZOXAZINONES - The present invention provides enantiomerically pure substituted (S)-benzoxazinone compounds and an extended release formulation of the compounds. The compounds exhibit potent renin inhibition activities and improved bioavailability. | 2009-12-17 |
20090311319 | Oral Preparation With Controlled Release - Abstract Oral preparation with controlled release A pharmaceutical pellet is provided, comprising a spherical core containing the active substance with a smooth surface and a coating on the core, which controls pH-independent release of the active substance. With a pellet of this kind, the release of the active substance may follow a profile with a lag-phase from 60 minutes to 840 minutes, where during the lag-phase a proportion of 5 wt. % or less of the active substance is released. Furthermore, the active substance may be released from the pellet with a profile such that, after the lag-phase, the release of the active substance is between and 25 wt. % per hour. The active substance is a metoprolol salt. | 2009-12-17 |
20090311320 | MULTILAYER ORALLY DISINTEGRATING TABLET - This invention pertains to an orally disintegrating multilayer tablet wherein it comprises at least two discrete layers, one of which comprises at least one active agent that promotes the oxidation of opioids, preferably acetaminophen, and the other of which contains granules including an inert core which is coated with at least one opioid and at least one binder, wherein said opioid coating is coated with a subcoat comprising a compound soluble in gastric fluids, said subcoat being coated with a taste-masking coating comprising a polymer or copolymer comprising dialkylaminoalkyl(meth)acrylate units and optionally a pore-forming agent. | 2009-12-17 |
20090311321 | ORAL DISINTEGRATING TABLET HAVING MASKED BITTER TASTE AND METHOD FOR PRODUCTION THEREOF - The present invention provides an orally disintegrating tablet containing mitiglinide calcium hydrate. The tablet has reduced bitterness and quickly disintegrates in the mouth, while exhibiting rapid dissolution in the digestive tract. The bitterness-masked orally disintegrating tablet comprises: (a) mitiglinide calcium hydrate; (b) microcrystalline cellulose; (c) at least one masking agent selected from the group consisting of aminoalkyl methacrylate copolymer E, polyvinylacetal diethylaminoacetate, an ethyl acrylate-methyl methacrylate copolymer, and ethyl cellulose; (d) a sugar or a sugar alcohol; and (e) at least one selected from corn starch and partially pregelatinized starch. | 2009-12-17 |
20090311322 | ATORVASTATIN FORMULATION - Provided are atorvastatin compositions which reduce the effect of food on the bioavailability of atorvastatin and methods for making such compositions. Also provided are methods of reducing low density lipoprotein by administering the compositions of the invention. | 2009-12-17 |